Management ChangeJun 8, 2026, 05:06 PM
Telomir Pharmaceuticals Appoints Andriy Mushak as Fractional CFO
AI Summary
Telomir Pharmaceuticals, Inc. announced a change in its Chief Financial Officer position. Alan Weichselbaum ceased serving as CFO effective June 6, 2026, with his departure not stemming from any disagreements. The company's board of directors appointed Andriy Mushak as the new fractional Chief Financial Officer, effective the same date. Mr. Mushak, a CPA with over 20 years of experience in SEC reporting and accounting, will provide his services through LMAM Consulting Group, LLC, for a monthly fee of $6,000.
Key Highlights
- Alan Weichselbaum ceased serving as CFO of Telomir Pharmaceuticals, Inc. effective June 6, 2026.
- His departure was not due to any disagreement with the company.
- Andriy Mushak was appointed as the company's fractional Chief Financial Officer, effective June 6, 2026.
- Mr. Mushak is a CPA with over 20 years of experience in SEC reporting, accounting compliance, and financial statement audits.
- He currently serves as a Partner at LMAM Consulting Group, LLC.
- Telomir Pharmaceuticals will pay Mr. Mushak $6,000 per month for his services.
- Mr. Mushak has no family relationships or material interests requiring disclosure.
Price Impact
More from TELO